Lenalidomide Improves Disease-Free Survival in Multiple Myeloma

Share this content:

(ChemotherapyAdvisor) – Maintenance therapy that included lenalidomide extended progression-free survival (PFS) in patients with multiple myeloma, three studies reported in the May 10, 2012, issue of the New England Journal of Medicine have concluded.

The multicenter, randomized, double-blind, placebo-controlled Phase 3 trials examined continuous lenalidomide treatment for patients with newly diagnosed multiple myeloma and lenalidomide as maintenance therapy after stem-cell transplantation.

  • Study 1 compared melphalan–prednisone–lenalidomide induction followed by lenalidomide maintenance (MPR-R; n=152) with melphalan–prednisone–lenalidomide (MPR; n=153) or melphalan–prednisone (MP; n=154) followed by placebo in patients ≥65 years of age with newly diagnosed multiple myeloma ineligible for transplantation. Median follow-up was 30 months. Median PFS was significantly longer with MPR-R (31 months) than with MPR (14 months; HR, 0.49; P<0.001) or MP (13 months; HR, 0.40; P<0.001). The greatest benefit was observed in patients ages 65 to 75 years.
  • Study 2 randomly assigned 460 patients <71 years of age with complete, partial, or marginal response or stable disease 100 days post-stem-cell transplantation to lenalidomide 10mg/day (starting dose; range, 5 to 15mg/day) or placebo, administered until disease progression. Median time to progression was 46 months in the lenalidomide group and 27 months in the placebo group (P<0.001). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%).
  • Study 3 randomly assigned 614 patients <65 years of age who had nonprogressive disease after first-line transplantation to maintenance treatment with lenalidomide (10mg/day for the first 3 months, increased to 15mg/day if tolerated) or placebo until relapse. Lenalidomide maintenance therapy was found to improve median PFS (41 months vs. 23 months with placebo; HR, 0.50; P<0.001). “This benefit was observed across all patient subgroups, including those based on the β2-microglobulin level, cytogenetic profile, and response after transplantation,” the investigators noted. Incidence of second primary cancers was 3.1 per 100 patient-years in the lenalidomide group vs. 1.2 per 100 patient-years in the placebo group (P=0.002).

An accompanying editorial found these studies to provide “compelling evidence of improvement” in PFS but “raise several critical questions,” including whether PFS is an appropriate primary endpoint in maintenance trials; whether lenalidomide maintenance therapy is safe, given the increased incidence of primary cancers; and whether it is cost-effective. The cost of lenalidomide is $163,381 annually “for the average patient.”

Study 1 (ClinicalTrials.gov number: NCT00405756)

Study 2 (ClinicalTrials.gov number: NCT00114101)

Study 3 (ClinicalTrials.gov number: NCT00430365)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs